Skip to content
Calculator

Grey-Market Encyclopedia · US warehouses

US warehouses and domestic stock

Some overseas sellers, often in China, keep stock in the United States and ship orders from there, so the buyer's own parcel never crosses a border. This page describes how that model works, what it changes, what it does not, and what FDA and CBP say about importing unapproved drugs. Described, not recommended.

Last updated October 28, 2026 · Reviewed by Grey Peptides Editorial Board · ✓ Every claim sourced · No products sold, no seller named

📋 Key takeaways

'Domestic stock' means a seller imported product in bulk and ships each order from inside the US. Mainstream e-commerce uses the same model: Chinese platforms pushed sellers in 2025 to bulk-ship to US warehouses and fulfil orders locally.12

It changes the last leg: the buyer's parcel is a domestic shipment, so it is not presented to CBP and FDA the way inbound international mail is, and it usually arrives sooner (our reasoning from how inbound mail is screened).95

It does not change what the product is. Selling an unapproved new drug inside the US is itself prohibited,1314 the vial was still made by whoever made it, and the bulk shipment still crossed the border, where FDA can detain it, including without examination under import alerts such as 66-41.34

A seller's 'US stock' claim is checkable from the carrier, the tracking history, the transit time and the return address; none of these says anything about what is in the vial (our reasoning).

On this page

  1. What 'domestic stock', 'US warehouse' and reshipping mean
  2. What it changes
  3. What it does not change
  4. Telling domestic from international shipping
  5. What CBP and FDA say about importing unapproved drugs
  6. Frequently asked questions
  7. Related on Grey Peptides
  8. Sources

What 'domestic stock', 'US warehouse' and reshipping mean

The three phrases describe one arrangement seen from different angles (our summary). Domestic stock (also 'US stock' or 'local stock') is a seller's claim that the product is already inside the United States. A US warehouse is where that stock sits: a space the seller or a partner controls, or a third-party fulfilment warehouse that stores goods and ships orders on a client's behalf. Reshipping is the step in which a person or business in the US receives goods from abroad and sends them on to the end customer, either one parcel at a time or by breaking down a larger consignment.

The general model has two legs. First, product made abroad is imported in bulk: one larger shipment instead of many small ones. Second, it is stored and fulfilled domestically: each order is packed in the US and handed to a US carrier. This is not peculiar to peptides. In April 2025, Rest of World reported that large Chinese shopping platforms were encouraging their sellers to stop sending parcels one by one from China and instead to bulk-ship products to US warehouses that store inventory and ship orders (news report).12 The shift followed the end of duty-free 'de minimis' treatment for low-value parcels: CBP's guidance says that from August 29, 2025, goods of all countries are no longer eligible for that exemption,10 and a presidential action of February 20, 2026 continued the suspension.11 Once every small parcel owes duty and a formal or informal entry, the per-parcel advantage of shipping direct shrinks, which makes bulk import relatively more attractive for any seller (our reasoning).

Sellers of grey-market peptides advertise the same arrangement, usually as faster delivery and fewer customs delays. We describe the claim generically and name no seller, warehouse or fulfilment company (our editorial rule).

What it changes

For the buyer, three things are different from a parcel sent direct from abroad.

  • Delivery time. A domestic parcel skips international transit and the inbound customs step, so it usually arrives in days rather than weeks (our reasoning; we found no published measurement for peptide parcels specifically).
  • No international shipment to the buyer. The buyer's own parcel starts and ends in the US. Inbound international mail is handled differently: the USPS Office of Inspector General states that "all inbound international mail is subject to CBP inspection", that the Postal Service must make it available to CBP, and that a mailpiece presented to CBP is scanned 'In Customs' for tracking.9 When an import is filed, "if the shipment contains FDA-regulated products, CBP sends data about those products to the FDA for review", and FDA's systems screen it electronically (FDA, content current as of January 21, 2026).5 A domestic parcel goes through neither step (our reasoning from the two documents).
  • Lower exposure of the buyer's own parcel at the border. The outcomes FDA describes for a refused personal import, a Notice of FDA Action and, for refused drugs worth $2,500 or less arriving by international mail or express courier, possible destruction without the option to export,2 attach to an imported shipment. A parcel that was never imported by the buyer is not in that process (our reasoning). Our customs seizures article explains the notice step by step.

That is the whole of the difference: the change is in where the border sits in the supply chain and who is on the import paperwork, not in the product (our reasoning, set out below).

What it does not change

Legal status

FDA's position on unapproved drugs applies inside the US, not only at the border. The Federal Food, Drug, and Cosmetic Act says "No person shall introduce or deliver for introduction into interstate commerce any new drug" unless an approved application is in effect,13 and it lists as prohibited acts both that introduction and "the receipt in interstate commerce" of a misbranded or adulterated drug "and the delivery or proffered delivery thereof for pay or otherwise".14 A peptide sold for people to use without approval is an unapproved new drug wherever it ships from (our reading of the statute; the legal risks page covers intended use and research-use labels). FDA's enforcement in this market is aimed at sellers and has reached US businesses: its GLP-1 page, current as of October 1, 2026, describes warnings to companies that sold unapproved drugs "falsely labeled 'for research purposes' or 'not for human consumption'", including telehealth companies and ingredient distributors.15 Moving stock into a US warehouse moves it into that jurisdiction rather than out of it (our reasoning).

Who made it, and its quality and testing

Domestic fulfilment changes where a vial was packed for posting, not where or how it was made (our reasoning). A product synthesised abroad and stored in the US carries the same manufacturing, the same lot and the same certificate it had before it was imported. Testing of products bought online shows why that matters: when researchers bought semaglutide vials from illegal online pharmacies, semaglutide made up only 7.7% to 14.37% of the powder, and the prefilled pens they ordered never arrived.17 FDA's administrative destruction page gives the same reason for destroying refused drugs: unapproved drugs have been found contaminated or counterfeit, or to contain varying amounts of active ingredient or a different one.2 A warehouse adds a storage step whose temperature and handling the buyer cannot see (our reasoning). Our physical risks page covers contamination, and how to check a seller's claims covers certificates.

Detention upstream, and stock-outs

The border is still crossed; only the buyer is no longer the one crossing it. Bulk imports of FDA-regulated products go through the same CBP filing and FDA review as any other entry, with release, examination, sampling or detention as the possible outcomes.5 FDA's import alerts let it detain future shipments from firms with a history of violations "without physical exam", which it calls DWPE.4 Import Alert 66-41, "Detention Without Physical Examination of Unapproved New Drugs Promoted In The U.S.", charges that such an article "appears to be a new drug" without approval, and says "commercial or promotional shipments, and products subject to DWPE are generally not amenable" to the discretion FDA applies to personal importation.3 CBP reports seizures of exactly this traffic: in a release of November 7, 2024, CBP officers in Cincinnati reported seizing a shipment from Hong Kong of 20 vials of semaglutide and 150 vials of tirzepatide, and CBP said it "works jointly with the FDA to combat the importation of illegal medications";7 in April 2026, local news reported that CBP officers in Cincinnati had intercepted about 5,000 shipments of unapproved peptides from China, carried in more than 300 larger cartons (news report).8 When an upstream shipment is detained, the buyer sees it not as a seizure notice but as an item that goes out of stock, an order that is delayed, or a substitution (our reasoning).

The buyer's recourse

A domestic return address does not make a seller of unapproved drugs easier to hold to account (our reasoning). The payment method decides most of what a buyer can do if an order is wrong or never comes: the FTC says "cryptocurrency payments do not come with legal protections" and "typically are not reversible".16 A seller's promise to replace lost or seized orders is its own policy, not an obligation, and a US warehouse does not change that; our financial risks page covers payment, chargebacks and non-delivery.

Telling domestic from international shipping

'Ships from the US' is a claim a seller makes, and like a purity figure it can be true or not. The signs below are what a buyer already sees on any order; they bear on whether the shipping claim is accurate, and on nothing else (our reasoning). They are described here as a way to judge what a seller says, not as a way to route anything past an inspection.

  • Carrier. A parcel posted in the US is handed to a US carrier from the start. A parcel from abroad usually begins with a foreign postal operator or an international express service, and may be handed to a US carrier only for final delivery (our reasoning).
  • Tracking origin. Domestic tracking begins with an acceptance scan at a US location. International tracking normally shows the origin country, an export step and an arrival scan in the US; mail presented to CBP is scanned 'In Customs' at a USPS International Service Center.9 A domestic-looking number that first appears only near the end of a longer journey can mean the US leg was the last of several (our reasoning).
  • Shipping time. An order that takes weeks, or pauses for days at a port-of-entry facility, is more consistent with an international shipment than with stock already in the country (our reasoning).
  • Return address. A US return address is easy to print and says little on its own, but a foreign return address, foreign-language labelling or a customs declaration on the box shows the parcel came from abroad (our reasoning). FDA notes that a label not in English can itself indicate a misbranded drug.2

Whichever way the answer comes out, it speaks only to the shipping claim. A parcel that truly came from a US shelf tells the buyer nothing about who made the vial, what is in it or whether it was tested (our reasoning, from the section above). A seller whose 'US stock' turns out to be shipped from abroad has made one claim that was not accurate, which is worth weighing against its other claims (our reasoning).

What CBP and FDA say about importing unapproved drugs

These are the regulators' own statements, with the dates their pages show. The legal risks page and our customs seizures article set them in context.

  • FDA, personal importation (content current as of August 18, 2025). "In most circumstances, it is illegal for individuals to import drugs or devices into the U.S. for personal use." FDA lists narrow situations in which its staff may use discretion, and says it would refuse a personal importation when the "product is on an FDA import alert for previous violations", when the "shipment appears to be intended for commercial distribution", or when it "appears to represent a health fraud".1
  • FDA, import alerts (content current as of March 3, 2025). "Import Alerts are used to protect consumers against products with a history of known violations"; FDA can detain later shipments of such products without examining them, which it calls "detention without physical exam" or DWPE.4
  • FDA, Import Alert 66-41 (page dated October 22, 2026; guidance last revised May 19, 2026). Titled "Detention Without Physical Examination of Unapproved New Drugs Promoted In The U.S." Its reason for alert: "Unapproved new drugs present public health and safety risks because they have not been reviewed by FDA for safety or effectiveness." Divisions "may detain without physical examination (DWPE), the identified products from the firms" it lists, and personal-importation discretion generally does not extend to commercial or promotional shipments or to products under DWPE.3 We describe the alert and do not reproduce its list of firms.
  • FDA, entry review (content current as of January 21, 2026). "If the shipment contains FDA-regulated products, CBP sends data about those products to the FDA for review"; FDA may release the product, examine or sample it, or request detention.5
  • FDA, administrative destruction (content current as of March 16, 2026). FDA may "destroy, without providing an opportunity for export, any refused drug valued at $2,500 or less" offered for import through international mail and express couriers; it sends a Notice of FDA Action with an opportunity to present testimony before refusal or destruction, and it "generally does not intend to pursue recovery of storage and destruction costs against individual consumers".2
  • CBP, seizure process (Federal Register notice effective May 16, 2023). When CBP seizes goods, it mails a Notice of Seizure, and "CBP will now publish the Notice of Seizure and Intent to Forfeit online" at about the same time rather than after the claim period ends. The person notified may file a petition with CBP, make an offer in compromise, or file a claim, which "means that the seizure will be transferred to a court for a judicial forfeiture process"; the notice "does not change any of the respective deadlines for filing for relief".6
  • CBP, on unapproved medications (release of November 7, 2024). "Imported drugs must meet FDA's standards for quality, safety, and effectiveness", and "CBP works jointly with the FDA to combat the importation of illegal medications."7

Read together, the documents describe controls aimed at the act of importing, applied to whoever is importing: an individual's parcel or a commercial consignment, with commercial and promotional shipments given less discretion, not more (our reading of the documents).13

Frequently asked questions

What does 'US warehouse' mean for peptides?

That a seller says its stock was imported in bulk and is shipped to buyers from inside the US. Mainstream e-commerce platforms moved many sellers to the same bulk-import model in 2025.12

Does domestic stock make an unapproved peptide legal?

No. The FD&C Act prohibits introducing an unapproved new drug into interstate commerce, which covers sales inside the US, and FDA has warned US companies selling such drugs.1315

Is a peptide from a US warehouse better quality?

Not because of the warehouse. Domestic fulfilment changes where the vial was posted, not who made it or how it was tested; one test of vials bought online found semaglutide was only 7.7% to 14.37% of the powder.17

Why do 'US stock' sellers run out of stock?

One reason is upstream: the bulk shipment still crosses the border, where FDA can detain it, including without examination under import alerts such as 66-41. We have no figures on how often this causes a stock-out.34

How can I tell whether my order really shipped from the US?

The carrier, where tracking begins, the transit time and the return address all bear on it; mail from abroad presented to CBP is scanned 'In Customs'. None of these tells you what is in the vial.9

Grey market hub Buyer's guide: start here Physical risks Financial risks Legal risks How buyers find sellers, and the scams The 2025 China crackdown Contamination and skin reactions What 'research use only' means Chinese peptides explained Peptide raves and group buys Peptides on Amazon, Temu and TikTok Shop How to evaluate a peptide vendor Purity is not safety Grey-market glossary

Sources

Statutes, regulators' pages, a CBP release and Federal Register notice are quoted with the dates they show; news is labelled as news. All read October 28, 2026. Where a sentence is our own inference it says '(our reasoning)'. This page describes the law and the logistics; it is not legal advice.

  1. U.S. Food and Drug Administration. Personal Importation (Import Basics). Content current as of August 18, 2025; read October 28, 2026. Source
  2. U.S. Food and Drug Administration. Administrative Destruction Authority (Import Basics). Content current as of March 16, 2026; read October 28, 2026. Source
  3. U.S. Food and Drug Administration. Import Alert 66-41, Detention Without Physical Examination of Unapproved New Drugs Promoted In The U.S. Page dated October 22, 2026; guidance last revised May 19, 2026; read October 28, 2026 (described; its list of firms is not reproduced). Source
  4. U.S. Food and Drug Administration. Import Alerts (Actions and Enforcement). Content current as of March 3, 2025; read October 28, 2026. Source
  5. U.S. Food and Drug Administration. Entry Review (FDA Import Process). Content current as of January 21, 2026; read October 28, 2026. Source
  6. U.S. Customs and Border Protection. Administrative Forfeiture: New Publication Timeline for the Notice of Seizure and Intent To Forfeit. General notice, Federal Register 88(94):31268-31269, effective May 16, 2023. Read October 28, 2026. Source
  7. U.S. Customs and Border Protection. Cincinnati CBP discovers more unapproved weight loss drugs. Local media release, November 7, 2024; read October 28, 2026. Source
  8. WHIO-TV. 5K shipments of unapproved weight loss injectable seized in Ohio. April 1, 2026, reporting a CBP Cincinnati announcement. News report; read October 28, 2026. Source
  9. U.S. Postal Service Office of Inspector General. Management Alert: U.S. Postal Service Handling of Inbound International Mail at the International Service Center. Report NO-MA-15-006, September 3, 2015. Read October 28, 2026. Source
  10. U.S. Customs and Border Protection. CSMS # 66065494, Guidance: Suspension of Duty-Free De Minimis Treatment for All Countries (effective August 29, 2025). Sent August 28, 2025; read October 28, 2026. Source
  11. The White House. Continuing the Suspension of Duty-Free De Minimis Treatment for All Countries. Presidential action, February 20, 2026; read October 28, 2026. Source
  12. Zhou V. Report on Chinese e-commerce platforms moving sellers to bulk shipping into US warehouses ahead of tariffs. Rest of World, April 23, 2025. News report; read October 28, 2026. Source
  13. 21 U.S.C. 355(a), New drugs: necessity of effective approval of application. Text read at the Legal Information Institute, October 28, 2026. Source
  14. 21 U.S.C. 331, Prohibited acts, subsections (a), (c) and (d). Text read at the Legal Information Institute, October 28, 2026. Source
  15. U.S. Food and Drug Administration. FDA's concerns with unapproved GLP-1 drugs used for weight loss. Content current as of October 1, 2026; read October 28, 2026. Source
  16. Federal Trade Commission. What To Know About Cryptocurrency and Scams. Consumer advice, last modified February 10, 2025; read October 28, 2026. Source
  17. Ashraf AR, et al. Multifactor Quality and Safety Analysis of Semaglutide Products Sold by Online Sellers Without a Prescription: Market Surveillance, Content Analysis, and Product Purchase Evaluation Study. J Med Internet Res. 2024;26:e65440. PMID 39509151; abstract read October 28, 2026. Source

This page describes how the grey market works; it is not legal or medical advice, and it is not a guide to buying. Grey Peptides sells nothing, links to no seller and rates none. If you have taken a product and feel unwell, contact a clinician or Poison Help (1-800-222-1222 in the US).